-
1.发明授权
公开(公告)号：EP2796421B1
公开(公告)日：2017-06-07
申请号：EP14165760.1
申请日：2014-04-24
Applicant: Corning Incorporated
Inventor： WEEKS, Wendell P. , SCHAUT, Robert Anthony , DEMARTINO, Steven Edward , PEANASKY, John Stephen
CPC classification number: A61J1/00 , A61K39/092 , A61K2039/6037 , C03C3/087 , C03C3/091 , C03C4/20 , C03C21/002
Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e ., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine).
Abstract translation: 本发明至少部分地基于对至少部分由玻璃组合物形成的药物容器的鉴定，所述玻璃组合物表现出降低的分层倾向，即降低了脱落玻璃颗粒的倾向。 结果，目前要求保护的容器特别适用于药物组合物的储存，特别是包含药物活性成分例如PREVNAR 13（肺炎球菌13价缀合物疫苗）的药物溶液。
-
2.发明授权
公开(公告)号：EP2771300B1
公开(公告)日：2017-12-20
申请号：EP12787986.4
申请日：2012-10-25
Applicant: Corning Incorporated
Inventor： WEEKS, Wendell P. , SCHAUT, Robert Anthony , DEMARTINO, Steven Edward , PEANASKY, John Stephen
CPC classification number: A61J1/1468 , A61J1/00 , A61J1/065 , A61K31/403 , A61K38/17 , A61K38/1816 , A61K38/193 , A61K38/28 , A61K39/3955 , C03C3/087 , C03C3/091 , C03C4/20 , C03C21/002 , C07K16/241 , Y02A50/463 , Y02A50/465 , Y10T428/131
Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, HUMIRA (Adalimumab).
-
3.发明公开
公开(公告)号：EP2796427A1
公开(公告)日：2014-10-29
申请号：EP14165860.9
申请日：2014-04-24
Applicant: Corning Incorporated
Inventor： WEEKS, Wendell P. , SCHAUT, Robert Anthony , DEMARTINO, Steven Edward , PEANASKY, John Stephen
CPC classification number: A61J1/00 , A61K38/1816 , B65D1/00 , C03C3/087 , C03C3/091 , C03C4/20 , C03C21/002 , C07K16/22 , C07K16/2863 , C07K16/2866 , C07K16/2875 , C07K2317/94
Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, Prolia® (denosumab), Xgeva® (denosumab), Aranesp® (darbepoetin alfa), AMG-145, romosozumab (AMG-785), ganitumab (AMG-479), trebananib (AMG-386), brodalumab (AMG-827), and rilotumumab (AMG-102).
Abstract translation: 本发明至少部分基于对至少部分由玻璃组合物形成的药物容器的鉴定，所述玻璃组合物表现出降低的分层倾向，即降低了脱落玻璃微粒的倾向。 结果，本发明要求保护的容器特别适用于储存药物组合物，具体地说，包含药物活性成分例如（（狄诺塞麦），（denosumab），（达贝泊汀α））， ，AMG-145，romosozumab（AMG-785），ganitumab（AMG-479），trebananib（AMG-386），brodalumab（AMG-827）和rilotumumab（AMG-102）。
-
4.发明公开
公开(公告)号：EP2796421A1
公开(公告)日：2014-10-29
申请号：EP14165760.1
申请日：2014-04-24
Applicant: Corning Incorporated
Inventor： WEEKS, Wendell P. , SCHAUT, Robert Anthony , DEMARTINO, Steven Edward , PEANASKY, John Stephen
CPC classification number: A61J1/00 , A61K39/092 , A61K2039/6037 , C03C3/087 , C03C3/091 , C03C4/20 , C03C21/002
Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e ., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine).
Abstract translation: 本发明至少部分基于对至少部分由玻璃组合物形成的药物容器的鉴定，所述玻璃组合物表现出降低的分层倾向，即降低了脱落玻璃微粒的倾向。 结果，目前要求保护的容器特别适用于药物组合物的储存，特别是包含药物活性成分例如PREVNAR 13（肺炎球菌13价缀合物疫苗）的药物溶液。
-
5.发明授权
公开(公告)号：EP2796429B1
公开(公告)日：2017-11-01
申请号：EP14165871.6
申请日：2014-04-24
Applicant: Corning Incorporated
Inventor： WEEKS, Wendell P. , SCHAUT, Robert Anthony , DEMARTINO, Steven Edward , PEANASKY, John Stephen
CPC classification number: A61J1/00 , A61K38/2221 , A61K39/095 , A61K2039/505 , A61K2039/54 , C03C3/087 , C03C3/091 , C03C4/20 , C03C21/002 , C07K16/22 , C07K16/244 , C07K2317/73 , C07K2317/94
-
Patent Agency Ranking6.发明授权
公开(公告)号：EP2796430B1
公开(公告)日：2017-06-07
申请号：EP14165872.4
申请日：2014-04-24
Applicant: Corning Incorporated
Inventor： WEEKS, Wendell P. , SCHAUT, Robert Anthony , DEMARTINO, Steven Edward , PEANASKY, John Stephen
CPC classification number: A61J1/00 , A61J1/1468 , A61K38/26 , A61K38/28 , A61K38/36 , B65D1/00 , C03C3/087 , C03C3/091 , C03C4/20 , C03C21/002 , C03C2204/00
Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e ., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, Victoza (liraglutide), Tresiba (insulin degludec), Ryzodeg (insulin degludec/insulin aspart), IDegLira (liraglutide and insulin degludec), NovoSeven (recombinant human coagulation factor VIIa), NovoSeven RT (recombinant human coagulation factor VIIa), or Turoctocog alfa (third-generation recombinant coagulation factor VIII).
Abstract translation: 本发明至少部分地基于对至少部分由玻璃组合物形成的药物容器的鉴定，所述玻璃组合物表现出降低的分层倾向，即降低了脱落玻璃颗粒的倾向。 结果，目前要求保护的容器特别适用于储存药物组合物，具体地说，包含药物活性成分例如Victoza（利拉鲁肽），Tresiba（degludec胰岛素），Ryzodeg（deggenc胰岛素/门冬胰岛素 ），IDegLira（利拉鲁肽和deggenc胰岛素），NovoSeven（重组人凝血因子VIIa），NovoSeven RT（重组人凝血因子VIIa）或Turoctocog alfa（第三代重组凝血因子VIII）。
-
7.发明公开
公开(公告)号：EP2796430A1
公开(公告)日：2014-10-29
申请号：EP14165872.4
申请日：2014-04-24
Applicant: Corning Incorporated
Inventor： WEEKS, Wendell P. , SCHAUT, Robert Anthony , DEMARTINO, Steven Edward , PEANASKY, John Stephen
CPC classification number: A61J1/00 , A61J1/1468 , A61K38/26 , A61K38/28 , A61K38/36 , B65D1/00 , C03C3/087 , C03C3/091 , C03C4/20 , C03C21/002 , C03C2204/00
Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e ., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, Victoza (liraglutide), Tresiba (insulin degludec), Ryzodeg (insulin degludec/insulin aspart), IDegLira (liraglutide and insulin degludec), NovoSeven (recombinant human coagulation factor VIIa), NovoSeven RT (recombinant human coagulation factor VIIa), or Turoctocog alfa (third-generation recombinant coagulation factor VIII).
Abstract translation: 本发明至少部分基于对至少部分由玻璃组合物形成的药物容器的鉴定，所述玻璃组合物表现出降低的分层倾向，即降低了脱落玻璃微粒的倾向。 结果，目前要求保护的容器特别适用于储存药物组合物，具体地说，包含药物活性成分例如Victoza（利拉鲁肽），Tresiba（degludec胰岛素），Ryzodeg（deggenc胰岛素/门冬胰岛素 ），IDegLira（利拉鲁肽和deggenc胰岛素），NovoSeven（重组人凝血因子VIIa），NovoSeven RT（重组人凝血因子VIIa）或Turoctocog alfa（第三代重组凝血因子VIII）。
-
8.发明授权
公开(公告)号：EP2805930B1
公开(公告)日：2017-11-01
申请号：EP14165870.8
申请日：2014-04-24
Applicant: Corning Incorporated
Inventor： WEEKS, Wendell P. , SCHAUT, Robert Anthony , DEMARTINO, Steven Edward , PEANASKY, John Stephen
CPC classification number: A61J1/00 , A61K31/166 , A61K31/4425 , A61K31/727 , A61K38/22 , A61K38/28 , B65D1/00 , C03C3/087 , C03C3/091 , C03C4/20 , C03C21/002 , C07K16/248 , C07K16/2893 , C07K16/40 , C07K2317/94
-
9.发明授权
公开(公告)号：EP2796427B1
公开(公告)日：2017-06-07
申请号：EP14165860.9
申请日：2014-04-24
Applicant: Corning Incorporated
Inventor： WEEKS, Wendell P. , SCHAUT, Robert Anthony , DEMARTINO, Steven Edward , PEANASKY, John Stephen
CPC classification number: A61J1/00 , A61K38/1816 , B65D1/00 , C03C3/087 , C03C3/091 , C03C4/20 , C03C21/002 , C07K16/22 , C07K16/2863 , C07K16/2866 , C07K16/2875 , C07K2317/94
Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, Prolia® (denosumab), Xgeva® (denosumab), Aranesp® (darbepoetin alfa), AMG-145, romosozumab (AMG-785), ganitumab (AMG-479), trebananib (AMG-386), brodalumab (AMG-827), and rilotumumab (AMG-102).
-
10.发明公开
公开(公告)号：EP2771294A1
公开(公告)日：2014-09-03
申请号：EP12783782.1
申请日：2012-10-25
Applicant: Corning Incorporated
Inventor： WEEKS, Wendell P. , SCHAUT, Robert Anthony , DEMARTINO, Steven Edward , PEANASKY, John Stephen
CPC classification number: A61J1/1468 , A61J1/00 , A61J1/065 , A61K31/403 , A61K38/17 , A61K38/1816 , A61K38/193 , A61K38/28 , A61K39/3955 , C03C3/087 , C03C3/091 , C03C4/20 , C03C21/002 , C07K16/241 , Y02A50/463 , Y02A50/465 , Y10T428/131
Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, HUMIRA (Adalimumab).
Abstract translation: 本发明至少部分基于对至少部分由玻璃组合物形成的药物容器的鉴定，所述玻璃组合物表现出降低的分层倾向，即降低了脱落玻璃微粒的倾向。 结果，目前要求保护的容器特别适用于药物组合物的储存，特别是包含药物活性成分的药物溶液，例如LEVEMIR，NOVOLOG，NOVOLIN 70-30，NOVOLIN R，NOVOLIN N，NOVOLOG MIX 70 -30和NOVOLIN L.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.023 seconds)
